Compare DDI & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DDI | CTNM |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.4M | 489.4M |
| IPO Year | 2020 | 2024 |
| Metric | DDI | CTNM |
|---|---|---|
| Price | $11.45 | $15.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $19.00 | $19.00 |
| AVG Volume (30 Days) | 93.9K | ★ 509.5K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.65 | N/A |
| Revenue Next Year | $2.64 | N/A |
| P/E Ratio | $4.31 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.10 | $3.72 |
| 52 Week High | $12.35 | $16.91 |
| Indicator | DDI | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 51.79 | 59.49 |
| Support Level | $11.25 | $10.95 |
| Resistance Level | $11.60 | $15.60 |
| Average True Range (ATR) | 0.21 | 1.20 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 80.77 | 70.94 |
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States, while it also has its presence in Canada, Germany, United Kingdom, and International-Other. The games offered by the company are: Doubledown Casion, Doubledown Fortknox, and Doubledown Classic Slots.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.